145 related articles for article (PubMed ID: 6435705)
1. Pathophysiological mechanisms of sudden death induced by platelet activating factor.
Lefer AM; Müller HF; Smith JB
Br J Pharmacol; 1984 Sep; 83(1):125-30. PubMed ID: 6435705
[TBL] [Abstract][Full Text] [Related]
2. Protective actions of a new thromboxane synthetase inhibitor in arachidonate induced sudden death.
Edmonds LC; Lefer AM
Life Sci; 1984 Oct; 35(17):1763-8. PubMed ID: 6434893
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary vascular response to platelet-activating factor in conscious sheep.
Toyofuku T; Kobayashi T; Koyama S; Kusama S
Am J Physiol; 1988 Sep; 255(3 Pt 2):H434-40. PubMed ID: 3414811
[TBL] [Abstract][Full Text] [Related]
4. In vivo enhancement of platelet activating factor-induced prostacyclin production by OKY-046, a selective inhibitor of thromboxane A2 synthase.
Davenport NJ; Goldstein RE; Feuerstein GZ
J Cardiovasc Pharmacol; 1991 Apr; 17(4):641-6. PubMed ID: 1711633
[TBL] [Abstract][Full Text] [Related]
5. CGS 15435A, a thromboxane synthetase inhibitor with an extended duration of action: a comparison with dazoxiben.
Olson RW; Cohen DS; Ku EC; Kimble EF; Renfroe HB; Smith EF
Eur J Pharmacol; 1987 Jan; 133(3):265-73. PubMed ID: 3104066
[TBL] [Abstract][Full Text] [Related]
6. Effect of 5-lipoxygenase and cyclooxygenase blockade on porcine hemodynamics during continuous infusion of platelet-activating factor.
Olson NC; Kruse-Elliott KT; Johnson LW
Prostaglandins Leukot Essent Fatty Acids; 1993 Aug; 49(2):549-59. PubMed ID: 8415804
[TBL] [Abstract][Full Text] [Related]
7. Cyclic blood flow variations induced by platelet-activating factor in stenosed canine coronary arteries despite inhibition of thromboxane synthetase, serotonin receptors, and alpha-adrenergic receptors.
Apprill P; Schmitz JM; Campbell WB; Tilton G; Ashton J; Raheja S; Buja LM; Willerson JT
Circulation; 1985 Aug; 72(2):397-405. PubMed ID: 2988822
[TBL] [Abstract][Full Text] [Related]
8. Sudden death induced by intracoronary platelet aggregation.
Yamazaki H; Isohisa I; Tanoue K
Jpn Circ J; 1983 May; 47(5):596-607. PubMed ID: 6406715
[TBL] [Abstract][Full Text] [Related]
9. Platelet activating factor stimulates cyclo-oxygenase activity in guinea pig eosinophils. Concerted biosynthesis of thromboxane A2 and E-series prostaglandins.
Giembycz MA; Kroegel C; Barnes PJ
J Immunol; 1990 May; 144(9):3489-97. PubMed ID: 2158510
[TBL] [Abstract][Full Text] [Related]
10. [Inhibitory effects of OKY-046.HCl, a selective thromboxane (TX) A2 synthetase inhibitor, on platelet activating factor (PAF)-induced airway hyperresponsiveness in guinea pigs].
Takehana Y; Hamano S; Kikuchi S; Kusama H; Komatsu H; Okegawa T; Ikeda S
Nihon Yakurigaku Zasshi; 1990 Jan; 95(1):21-30. PubMed ID: 2303203
[TBL] [Abstract][Full Text] [Related]
11. Protective actions of ibuprofen in arachidonate-induced sudden death.
Roth DM; Burke SE; Lefer AM
Pharmacology; 1983; 27(3):169-75. PubMed ID: 6413987
[TBL] [Abstract][Full Text] [Related]
12. CGS 12970: a novel, long acting thromboxane synthetase inhibitor.
Ambler J; Butler KD; Ku EC; Maguire ED; Smith JR; Wallis RB
Br J Pharmacol; 1985 Oct; 86(2):497-504. PubMed ID: 2932197
[TBL] [Abstract][Full Text] [Related]
13. Enhanced glomerular thromboxane A2 mediates some pathophysiologic effect of platelet-activating factor in rabbit nephrotoxic nephritis: evidence from biochemical measurements and inhibitor trials.
Macconi D; Benigni A; Morigi M; Ubiali A; Orisio S; Livio M; Perico N; Bertani T; Remuzzi G; Patrono C
J Lab Clin Med; 1989 May; 113(5):549-60. PubMed ID: 2541212
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of a new specific thromboxane antagonist in arachidonate-induced sudden death.
Lefer DJ; Mentley RK; Lefer AM
Arch Int Pharmacodyn Ther; 1987 May; 287(1):89-95. PubMed ID: 2957969
[TBL] [Abstract][Full Text] [Related]
15. Thromboxane rather than platelet activating factor mediates pulmonary vasoconstriction after antigen challenge in rabbits.
Enzan K; Kurosawa S; Yoshioka N; Inaba H
Shock; 1996 Sep; 6(3):183-7. PubMed ID: 8885083
[TBL] [Abstract][Full Text] [Related]
16. A comparison of human pulmonary arterial and venous prostacyclin and thromboxane synthesis--effect of a thromboxane synthase inhibitor.
Carter AJ; Bevan JA; Hanley SP; Morgan WE; Turner DR
Thromb Haemost; 1984 Apr; 51(2):257-60. PubMed ID: 6377567
[TBL] [Abstract][Full Text] [Related]
17. Methacholine-induced contraction of rabbit pulmonary artery: role of platelet-endothelial transcellular thromboxane synthesis.
Pfister SL; Deinhart DD; Campbell WB
Hypertension; 1998 Jan; 31(1 Pt 2):206-12. PubMed ID: 9453304
[TBL] [Abstract][Full Text] [Related]
18. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
[TBL] [Abstract][Full Text] [Related]
19. Glomerular prostaglandin and thromboxane synthesis in rat nephrotoxic serum nephritis. Effects on renal hemodynamics.
Lianos EA; Andres GA; Dunn MJ
J Clin Invest; 1983 Oct; 72(4):1439-48. PubMed ID: 6685136
[TBL] [Abstract][Full Text] [Related]
20. Primed stimulation of isolated perfused rabbit lung by endotoxin and platelet activating factor induces enhanced production of thromboxane and lung injury.
Salzer WL; McCall CE
J Clin Invest; 1990 Apr; 85(4):1135-43. PubMed ID: 2318970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
